profit from every $100 of sales.
$0$100
Vaxart
$0.36-1.10% today
-2.4% in 1 year
1-year low $0.351-year high $0.80
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $5.39 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Vaxart sold, what it kept, and what it did with the cash.
Sales went from $107,000 in 2022 to $237 million in 2025, with $16.3 million of profit last year.
SalesProfit
Vaxart vs. similar companies
Vaxart grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Vaxart | 5.4× · Cheap | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Vaxart's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 7 | 29 | 237 | |
| – | – | – | – | |
| -110 | -83 | -66 | 18 | |
| -101 | -72 | -55 | 28 | |
| -108 | -82 | -67 | 16 | |
| -0.84 | -0.57 | -0.33 | 0.07 | |
| – | – | – | – | |
| -103,115.0% | -1,129.5% | -231.0% | 7.6% | |
| -100,708.4% | -1,117.6% | -233.3% | 6.9% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 154 | 92 | 166 | 186 |
| Cash | 46 | 35 | 25 | 54 |
| Total debt | 22 | 20 | 18 | 9 |
| Total liabilities | 43 | 34 | 107 | 98 |
| 111 | 58 | 59 | 88 | |
| 128 | 145 | 202 | 230 | |
| -63.5% | -81.9% | -65.8% | 16.0% | |
| -97.4% | -142.7% | -113.6% | 18.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -95 | -70 | -45 | 8 | |
| 10 | 2 | 1 | 0 | |
| -104 | -72 | -45 | 8 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 14 | 14 | 12 | 8 |
Valuation
- 5.4×
- –
- –
- 1.7×
- 0.4×
- 11.6×
- 1.5×
- 8.6%
- 18.6%
- 0.0%
Profitability
- 100.0%
- 7.6%
- 6.9%
- 18.5%
- 35.7%
- -54.7%
- 61.4%
- 20.6%
- 37.0%
- 78.3%
Growth
- +1,204.0%
- –
- +116.7%
- –
- −17.1%
Financial health
- -0.9×
- 0.08
- 4.4%
- 16.4×
- 1.71
- 1.71
- 1.42
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 2%of 958
Bottom 44%of 888
Top 2%of 600
Top 11%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 0.02 | 0.02 | +0.0% |
| Mar 12, 2026 | 0.24 | -0.08 | +400.0% |
| Nov 13, 2025 | -0.04 | -0.07 | +42.9% |
| Aug 13, 2025 | -0.07 | -0.09 | +22.2% |
| May 13, 2025 | -0.07 | -0.07 | +0.0% |
| Mar 20, 2025 | -0.05 | -0.10 | +50.0% |
| Nov 13, 2024 | -0.06 | -0.10 | +40.0% |
| Aug 8, 2024 | -0.09 | -0.03 | −237.5% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
6/7Passes 6 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
61Pass
Benjamin Graham
69Pass
Philip Fisher
63Pass
Peter Lynch
76Pass
Joel Greenblatt
91Pass
Charlie Munger
63Pass
Terry Smith
54No pass
Questions about Vaxart
Is Vaxart a good stock to buy?
A business with weak numbers, and the price looks low. 6 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Vaxart AI analysis
What does Vaxart do?
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. It is in Biotechnology.
Does Vaxart pay a dividend?
No. Vaxart does not pay a dividend at the moment.
Is Vaxart stock halal?
No. Vaxart does not pass our halal screen: its cash and confirmed interest-bearing investments are 61% of its market value, at or above the 33% limit. How we check
How has Vaxart stock done over the past year?
Down 2.4% over the past twelve months, to $0.36. It traded between $0.35 and $0.80 and is 54.9% below its high.
Who are Vaxart's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Vaxart's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.